Patterns of multispecialty care for low- and intermediate-risk prostate cancer in the use of active surveillance

被引:0
|
作者
Zambrano, Ibardo A. [1 ]
Hwang, Soohyun [2 ]
Basak, Ram [1 ]
Spratte, Brooke Namboodri [1 ]
Filson, Christopher P. [3 ]
Jacobs, Bruce L. [4 ]
Tan, Hung-Jui [1 ]
机构
[1] Univ N Carolina, Dept Urol, Chapel Hill, NC 27599 USA
[2] Univ N Carolina, Dept Hlth Policy & Management, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA
[3] Emory Univ, Dept Urol, Sch Med, Atlanta, GA USA
[4] Univ Pittsburgh, Dept Urol, Pittsburgh, PA USA
关键词
Prostate cancer; Active surveillance; SEER Medicare; Multispecialty care; Referral; Consultation; MODULATED RADIATION-THERAPY; UROLOGISTS; RECOMMENDATIONS; ONCOLOGISTS;
D O I
10.1016/j.urolonc.2023.04.024
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Multidisciplinary models of care have been advocated for prostate cancer (PC) to promote shared decision-making and facilitate quality care. Yet, how this model applies to low-risk disease where the preferred management is expectant remains unclear. Accordingly, we examined recent practice patterns in specialty visits for low/intermediate-risk PC and resultant use of active surveillance (AS). Methods: Using SEER-Medicare, we ascertained whether patients saw urology and radiation oncology (i.e., multispecialty care) versus urology alone, based on self-designated specialty codes, for newly diagnosed PC from 2010 to 2017. We also examined the association with AS, defined as the absence of treatment within 12 months of diagnosis. Time trends were analyzed using Cochran-Armitage test. Chi squared and logistic regression analyses were applied to compare sociodemographic and clinicopathologic characteristics between these models of care. Results: The proportion of patients seeing both specialists was 35.5% and 46.5% for low- and intermediate-risk patients respectively. Trend analysis showed a decline in multispecialty care in low-risk patients (44.1% to 25.3% years 2010-2017; P < 0.001). Between 2010 and 2017, the use of AS increased 40.9% to 68.6% (P < 0.001) and 13.1% to 24.6% (P < 0.001) for patients seeing urology and those seeing both specialists respectively. Age, urban residence, higher education, SEER region, co-morbidities, frailty, Gleason score, predicted receipt of multispecialty care (all P < 0.02). Conclusions: Uptake of AS among men with low-risk PC has occurred primarily under the purview of urologists. While selection is certainly at play, these data suggest that multispecialty care may not be required to promote the utilization of AS for men with low-risk PC. 0 2023 Elsevier Inc. All rights reserved.
引用
收藏
页码:388.e1 / 388.e8
页数:8
相关论文
共 50 条
  • [31] Use of Active Surveillance vs Definitive Treatment Among Men With Low- and Favorable Intermediate-Risk Prostate Cancer in the US Between 2010 and 2018
    Al Awamlh, Bashir Al Hussein
    Barocas, Daniel A. A.
    Zhu, Alec
    Tosoian, Jeffrey J. J.
    Ponsky, Lee
    Negoita, Serban
    Shoag, Jonathan E. E.
    JAMA INTERNAL MEDICINE, 2023, 183 (06) : 608 - 611
  • [32] Are men with favorable intermediate-risk prostate cancer candidates for active surveillance?
    Raldow, Ann Caroline
    Zhang, Danjie
    Chen, Ming-Hui
    Braccioforte, Michelle H.
    Moran, Brian Joseph
    D'Amico, Anthony Victor
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [33] Active Surveillance in Intermediate-Risk Prostate Cancer: A Review of the Current Data
    Blas, Leandro
    Shiota, Masaki
    Eto, Masatoshi
    CANCERS, 2022, 14 (17)
  • [34] Management of intermediate-risk prostate cancer with active surveillance: never or sometimes?
    Masic, Selma
    Washington, Samuel L., III
    Carroll, Peter R.
    CURRENT OPINION IN UROLOGY, 2017, 27 (03) : 231 - 237
  • [35] Active Surveillance-Is It Feasible for Intermediate-risk Localised Prostate Cancer?
    Mukherjee, Subhabrata
    Promponas, Ioannis
    Petrides, Neophytos
    Hossain, Dafader
    Abbaraju, Jayasimha
    Madaan, Sanjeev
    EUROPEAN UROLOGY OPEN SCIENCE, 2021, 24 : 17 - 24
  • [36] Long-term and pathological outcomes of low- and intermediate-risk prostate cancer after radical prostatectomy: implications for active surveillance
    Valentin H. Meissner
    Mira Woll
    Donna P. Ankerst
    Stefan Schiele
    Jürgen E. Gschwend
    Kathleen Herkommer
    World Journal of Urology, 2021, 39 : 3763 - 3770
  • [37] Performance of MRI-TRUS-guided fusion biopsy to detect progression on active surveillance for low- and intermediate-risk prostate cancer
    Frye, Thomas P.
    Shakir, Nabeel Ahmad
    Abboud, Steven
    George, Arvin Koruthu
    Merino, Maria J.
    Choyke, Peter L.
    Turkbey, Baris
    Wood, Bradford J.
    Pinto, Peter A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [38] Termination rates and histological reclassification of active surveillance patients with low- and early intermediate-risk prostate cancer: results of the PREFERE trial
    Albers, Peter
    Wiegel, Thomas
    Schmidberger, Heinz
    Bussar-Maatz, Roswitha
    Haerter, Martin
    Kristiansen, Glen
    Martus, Peter
    Meisner, Christoph
    Wellek, Stefan
    Grozinger, Klaus
    Renner, Peter
    Burmester, Martin
    Schneider, Fried
    Stoeckle, Michael
    WORLD JOURNAL OF UROLOGY, 2021, 39 (01) : 65 - 72
  • [39] Long-term and pathological outcomes of low- and intermediate-risk prostate cancer after radical prostatectomy: implications for active surveillance
    Meissner, Valentin H.
    Woll, Mira
    Ankerst, Donna P.
    Schiele, Stefan
    Gschwend, Juergen E.
    Herkommer, Kathleen
    WORLD JOURNAL OF UROLOGY, 2021, 39 (10) : 3763 - 3770
  • [40] Termination rates and histological reclassification of active surveillance patients with low- and early intermediate-risk prostate cancer: results of the PREFERE trial
    Peter Albers
    Thomas Wiegel
    Heinz Schmidberger
    Roswitha Bussar-Maatz
    Martin Härter
    Glen Kristiansen
    Peter Martus
    Christoph Meisner
    Stefan Wellek
    Klaus Grozinger
    Peter Renner
    Martin Burmester
    Fried Schneider
    Michael Stöckle
    World Journal of Urology, 2021, 39 : 65 - 72